Literature DB >> 30901551

A Tumor-Agnostic NTRK (TRK) Inhibitor.

Franklin W Huang1, Felix Y Feng2.   

Abstract

Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30901551     DOI： 10.1016/j.cell.2019.02.049

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  6 in total

1.  BDNF/TRKB axis provokes EMT progression to induce cell aggressiveness via crosstalk with cancer-associated fibroblasts in human parotid gland cancer.

Authors:  Kazumasa Moriwaki; Masaki Wada; Hiroko Kuwabara; Yusuke Ayani; Tetsuya Terada; Masaaki Higashino; Ryo Kawata; Michio Asahi
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 2.  Small molecule inhibitors targeting the cancers.

Authors:  Gui-Hong Liu; Tao Chen; Xin Zhang; Xue-Lei Ma; Hua-Shan Shi
Journal:  MedComm (2020)       Date:  2022-10-13

3.  Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement.

Authors:  Valentina Nardi; Nora Ku; Matthew J Frigault; Adrian M Dubuc; Harrison Kwei Tsai; Philip C Amrein; Gabriela S Hobbs; Andrew M Brunner; Rupa Narayan; Meghan E Burke; Julia Foster; Paola Dal Cin; Marcela V Maus; Amir T Fathi; Hanno Hock
Journal:  Blood Adv       Date:  2020-01-14

Review 4.  Chemotherapy in NEN: still has a role?

Authors:  Paula Espinosa-Olarte; Anna La Salvia; Maria C Riesco-Martinez; Beatriz Anton-Pascual; Rocio Garcia-Carbonero
Journal:  Rev Endocr Metab Disord       Date:  2021-04-11       Impact factor: 9.306

5.  SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.

Authors:  Tamara Rothenburger; Katie-May McLaughlin; Tobias Herold; Constanze Schneider; Thomas Oellerich; Florian Rothweiler; Andrew Feber; Tim R Fenton; Mark N Wass; Oliver T Keppler; Martin Michaelis; Jindrich Cinatl
Journal:  Commun Biol       Date:  2020-06-24

6.  A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.

Authors:  Jeffrey M Conroy; Sarabjot Pabla; Sean T Glenn; R J Seager; Erik Van Roey; Shuang Gao; Blake Burgher; Jonathan Andreas; Vincent Giamo; Melissa Mallon; Yong Hee Lee; Paul DePietro; Mary Nesline; Yirong Wang; Felicia L Lenzo; Roger Klein; Shengle Zhang
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.